Defunct Company
Total Trials
13
As Lead Sponsor
12
As Collaborator
1
Total Enrollment
3,251
NCT01987817
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 6, 2014
Completion: Jan 7, 2015
NCT02198664
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
Start: Aug 27, 2014
Completion: Jan 4, 2018
NCT02635776
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Phase: Phase 3
Start: Dec 22, 2015
Completion: Jul 2, 2018
NCT02993107
PALISADE Follow-on Study (ARC004)
Start: Dec 29, 2016
Completion: May 31, 2019
NCT03126227
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Start: May 8, 2017
Completion: Sep 23, 2018
NCT03201003
ARTEMIS Peanut Allergy In Children
Start: Jun 12, 2017
Completion: Feb 15, 2019
NCT03337542
AR101 Real-World Open-Label Extension Study
Start: Oct 18, 2017
Completion: Sep 20, 2019
NCT03292484
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
Start: Nov 2, 2017
Completion: Apr 27, 2023
NCT03682770
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Role: Collaborator
Start: Oct 3, 2018
Completion: Jul 23, 2021
NCT03703791
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
Start: Oct 24, 2018
Completion: Nov 23, 2018
NCT03736447
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Start: Dec 27, 2018
Completion: Jul 5, 2022
NCT04056299
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Start: Aug 20, 2019
Completion: Dec 28, 2020
NCT07218640
Aimmune Longitudinal Collaboration Study
Phase: N/A
Start: Oct 31, 2025
Completion: Jul 31, 2026